Written by Lisa Loud
We stand at the precipice of a medical revolution. Artificial intelligence is no longer a futuristic concept confined to research labs; it is actively transforming the biotechnology landscape. From accelerating drug discovery to optimizing clinical trials, and from decoding the human genome to delivering personalized precision medicine, AI is rewriting the rules of what is possible in healthcare. Yet, as we embrace this unprecedented potential, we are simultaneously colliding with a monumental barrier: the profound tension between data utility and data privacy.
I have spent years at the intersection of privacy-preserving technology and real-world product development. Today, much of that work is grounded in women’s health. As Chief Operations Officer at UmmuHub — a platform that uses epigenetic data and AI to deliver personalized health insights for women across every life stage — I have a front-row seat to both the extraordinary promise of AI in life sciences and the very real structural barriers that prevent it from reaching its potential. The question I return to constantly is not whether AI will revolutionize biotech, but whether we are building the infrastructure of trust necessary to let it.
The promise is genuinely staggering. Consider drug discovery, traditionally a decades-long, multi-billion-dollar endeavor fraught with high failure rates. AI algorithms can now analyze vast datasets of chemical compounds and biological interactions to predict which molecules are most likely to succeed as therapeutics. In genomics and epigenetics, machine learning models are identifying complex patterns within DNA sequences, unlocking insights into rare diseases and genetic predispositions that were previously invisible to human researchers. AI is also streamlining clinical trials by identifying suitable candidates more efficiently and predicting potential adverse reactions before they occur.
Working on UmmuHub has made these dynamics viscerally concrete for me. Women’s health has historically been one of the most underserved areas in biomedical research. Most genetic and epigenetic datasets were built on mixed or male-majority samples, meaning the algorithms trained on them learned the average body — not the female body. Female biology is cyclical, hormonally dynamic, and life-stage dependent. Oestrogen shifts methylation. Pregnancy rewires metabolism. Perimenopause changes inflammatory signalling. When you average that complexity with male data, female-specific signals get diluted. What looks like a neutral model is often just male-biased math.
At UmmuHub, we built from the ground up to correct for this. The platform analyzes over a thousand biomarkers from a saliva-based epigenetic test, generates a biological age score trained exclusively on female samples, and uses AI to translate those results into personalized nutrition, supplementation, and lifestyle protocols. The AI coach knows a user’s epigenetic results, her life stage, and her specific variants — and it answers from that data, not from generic population averages. That is what precision medicine actually looks like in practice.
But here is the challenge that keeps me up at night. To build AI models that are genuinely accurate and unbiased across diverse female populations — across ethnicities, geographies, and life stages — we need data. Vast amounts of it. And that data is among the most sensitive information a person can share: their DNA, their methylation patterns, their hormonal rhythms, their reproductive history. The fear of misuse is not paranoia; it is rational. Patients and users are right to ask hard questions about where their biological data goes, who can access it, and whether their consent is truly meaningful.
This is where the architecture of the technology matters as much as the science itself. The dominant model in health data today — centralize everything, build walls around it, and hope the walls hold — is fundamentally inadequate. Data breaches are not edge cases; they are inevitable at scale. And for women sharing epigenetic data tied to fertility, pregnancy, and hormonal health, the consequences of a breach are not merely inconvenient. They are deeply personal.
The solution is not to collect less data. It is to change how data is processed. Confidential computing — and specifically technologies like Trusted Execution Environments (TEEs) — allows data to be analyzed while it remains encrypted. An AI model can be trained on a user’s epigenetic profile without the researchers, developers, or hardware providers ever seeing the raw information. The computation happens inside a secure enclave; only the output — the insight, the recommendation, the aggregated finding — ever leaves it.
Imagine what this unlocks at scale. Multiple research institutions could collaborate on understanding female biological aging across thousands of epigenetic samples without any single party gaining access to the underlying records. A platform like UmmuHub could contribute to population-level research on reproductive health, hormonal patterns, or longevity without compromising the privacy of a single user. The AI model travels to the data rather than the data traveling to the model. That inversion is not a technical detail; it is a paradigm shift.
Complementary technologies extend this further. Blockchain provides the immutable ledger for consent management and data provenance, ensuring that individuals retain genuine ownership and control over how their data is used. Zero-Knowledge Proofs allow a system to verify a claim — this user meets the study criteria, this result falls within a healthy range — without revealing the underlying data at all. Together, these tools make it possible to build AI systems in biotech that are both powerful and trustworthy.
The integration of AI and life sciences holds the promise of curing the incurable and extending the human healthspan. But that promise will remain partially locked away as long as patients and users cannot trust the systems that hold their most intimate data. In women’s health, I have seen firsthand how trust is the prerequisite for participation, and participation is the prerequisite for the diverse, representative data that makes AI actually work.
Privacy is not a constraint on innovation. It is the condition that makes meaningful innovation possible. And in the age of AI-driven biotech, building that foundation is not optional. It is the work.
